Your browser doesn't support javascript.
loading
An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation.
Yu, Shengze; Alkharusi, Amira; Norstedt, Gunnar; Gräslund, Torbjörn.
Affiliation
  • Yu S; Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Alkharusi A; College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
  • Norstedt G; College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
  • Gräslund T; Center for Molecular Medicine, Karolinska Institute, Solna, Stockholm, Sweden.
PLoS One ; 14(5): e0215831, 2019.
Article in En | MEDLINE | ID: mdl-31063493
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prolactin / Receptors, Prolactin / STAT5 Transcription Factor Limits: Animals / Humans / Male Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2019 Document type: Article Affiliation country: Sweden Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prolactin / Receptors, Prolactin / STAT5 Transcription Factor Limits: Animals / Humans / Male Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2019 Document type: Article Affiliation country: Sweden Country of publication: United States